IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
Licensing/Co-Marketing Agreements
Marketed Products
Product Class Date Terms of Agreement
Lialda (mesalamine) A 2008 Shire and TAP (dissolved in May 2008) to copromote
Lialda (for ulcerative colitis) in the US under 3-yr
agreement.
Provigil (modafinil) N 2006 Cephalon and Takeda entered into an agreement under
which Takeda will co-promote Provigil in the USA. The
three-year deal will have an option to renew annually.
Cephalon will pay Takeda a royalty based on certain sales
criteria for both products. Cephalon will retain all
responsibility for development, distribution and sales of
modafinil.
Prevacid (lansoprazole) A 2006 TAP has granted Novartis the right to develop an OTC
version of Prevacid in the US. Novartis will take full
responsibility for the switch-OTC program, including the
design and conduct of clinical studies, regulatory
submissions to the FDA and manufacturing, distribution
and launch activities. Financial arrangements were
undisclosed.
Glufast (mitiglinide) A 2004 Kissei will co-market the agent in Japan in collaboration
with Takeda. Licensee Servier acquired rights to develop
this agent in Europe, the Middle East, Africa, Oceania,
and Asian countries, excluding Japan, China, Taiwan, and
Korea.
Actos A 2004 Takeda and Andrx agreed to co-develop a product
combining Actos with Andrx’s Fortamet (metformin
extended release).Once approved, it will be
manufactured by Andrx. Exclusive marketing rights will
be held by Takeda, which will be responsible for
approvals. Andrx will receive $10 million as an initial
payment, and be eligible for additional milestone, royalty
and performance payments.
© 2009 IMS Health In cor po rated or its af fil i ates Page 91